LOS ANGELES, CA / ACCESS Newswire / February 8, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
Rare Disease Revenue: $8.8 billion in 2024, up 16%. AstraZeneca PLC (NASDAQ:AZN) reported a strong financial performance in 2024, with total revenue up 21% and core EPS up 19%, indicating robust ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results